Scarica l'app Stockscreener
143.21
3.75%
5.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$138.04
Aprire:
$138.04
Volume 24 ore:
1.33M
Relative Volume:
1.45
Capitalizzazione di mercato:
$14.20B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
48.55
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
-0.55%
1M Prestazione:
+2.02%
6M Prestazione:
+32.98%
1 anno Prestazione:
+19.07%
Intervallo 1D:
$137.06
$143.47
Intervallo di 1 settimana:
$133.61
$149.98
Portata 52W:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
143.21 | 13.76B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
How big funds are accumulating Neurocrine Biosciences Inc. (NB3) stock2025 Trade Ideas & Safe Entry Momentum Stock Tips - newser.com
How risky is Neurocrine Biosciences Inc. stock nowInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
What analysts say about Neurocrine Biosciences Inc stockMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Is Neurocrine Biosciences Inc a good long term investmentEarnings Date Calendar & Register for the Next Free Workshop - earlytimes.in
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherMarket Sentiment Report & Free Daily Entry Point Trade Alerts - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s futureJuly 2025 Sentiment & AI Based Buy/Sell Signal Reports - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Market Risk Analysis & Accurate Entry and Exit Point Alerts - newser.com
Cantor Fitzgerald Brokers Raise Earnings Estimates for NBIX - MarketBeat
Brighton Jones LLC Invests $351,000 in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Short interest data insights for Neurocrine Biosciences Inc.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
Neurocrine Biosciences (NASDAQ:NBIX) Given Buy Rating at Truist Financial - MarketBeat
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levels2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyTake Profit & Real-Time Chart Pattern Alerts - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikesMarket Growth Review & Consistent Profit Focused Trading Strategies - newser.com
Jennison Associates LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Applying sector rotation models to Neurocrine Biosciences Inc.Market Performance Summary & Fast Exit and Entry Trade Guides - newser.com
What analysts say about Neurocrine Biosciences Inc NB3 stockHealthcare Stock Analysis & Minimal Capital Trading Tips - earlytimes.in
Is The Indian Link Chain Manufactures Limited a Growth Buy or Value Trap This YearFundamental Strength Indicators & Free Daily Stock Hotspot Analysis - earlytimes.in
What moving averages say about Neurocrine Biosciences Inc.July 2025 News Drivers & Consistent Growth Stock Picks - newser.com
INGREZZA and CRENESSITY Sales Beat Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Given New $164.00 Price Target at Canaccord Genuity Group - MarketBeat
Focus Partners Advisor Solutions LLC Takes $660,000 Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Citigroup Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownWhat's Next? - MarketBeat
Piper Sandler Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Needham & Company LLC Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call Transcript - Insider Monkey
How to build a dashboard for Neurocrine Biosciences Inc. stockPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Neurocrine Biosciences (NBIX): Net Margin Miss Challenges Bullish Earnings Growth Narratives - Yahoo Finance
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 8,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Can Neurocrine Biosciences Inc. stock sustain revenue growthJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
Piper Sandler Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - Nasdaq
Is Now the Right Time to Reassess Neurocrine Biosciences After Expansion News and Valuation Gaps? - simplywall.st
Neurocrine Biosciences (NBIX): Evaluating Valuation After Q3 Earnings Beat and Pipeline Progress - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Issues Earnings Results - MarketBeat
Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression - TipRanks
Wedbush Raises Price Target on Neurocrine Biosciences to $149 From $143, Keeps Outperform Rating - MarketScreener
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating - MarketScreener
Needham Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating - MarketScreener
Sumitomo Mitsui Trust Group Inc. Buys 4,030 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
1.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):